These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

983 related articles for article (PubMed ID: 27084936)

  • 21. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics.
    Xu L; Anchordoquy T
    J Pharm Sci; 2011 Jan; 100(1):38-52. PubMed ID: 20575003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don't.
    Juliano RL
    Nucleic Acid Ther; 2018 Jun; 28(3):166-177. PubMed ID: 29708838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cationic polymer based nanocarriers for delivery of therapeutic nucleic acids.
    Nimesh S; Gupta N; Chandra R
    J Biomed Nanotechnol; 2011 Aug; 7(4):504-20. PubMed ID: 21870455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking.
    Mangla P; Vicentini Q; Biscans A
    Cells; 2023 Sep; 12(18):. PubMed ID: 37759475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delivery of oligonucleotide-based therapeutics: challenges and opportunities.
    Hammond SM; Aartsma-Rus A; Alves S; Borgos SE; Buijsen RAM; Collin RWJ; Covello G; Denti MA; Desviat LR; Echevarría L; Foged C; Gaina G; Garanto A; Goyenvalle AT; Guzowska M; Holodnuka I; Jones DR; Krause S; Lehto T; Montolio M; Van Roon-Mom W; Arechavala-Gomeza V
    EMBO Mol Med; 2021 Apr; 13(4):e13243. PubMed ID: 33821570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders.
    Aupy P; Echevarría L; Relizani K; Goyenvalle A
    Biomedicines; 2017 Dec; 6(1):. PubMed ID: 29271929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions.
    Astriab-Fisher A; Sergueev D; Fisher M; Shaw BR; Juliano RL
    Pharm Res; 2002 Jun; 19(6):744-54. PubMed ID: 12134943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides.
    Juliano RL; Carver K; Cao C; Ming X
    J Drug Target; 2013 Jan; 21(1):27-43. PubMed ID: 23163768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted delivery of a splice-switching oligonucleotide by cationic polyplexes of RGD-oligonucleotide conjugate.
    Ming X; Feng L
    Mol Pharm; 2012 May; 9(5):1502-10. PubMed ID: 22497548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The current landscape of nucleic acid therapeutics.
    Kulkarni JA; Witzigmann D; Thomson SB; Chen S; Leavitt BR; Cullis PR; van der Meel R
    Nat Nanotechnol; 2021 Jun; 16(6):630-643. PubMed ID: 34059811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vectorization of Nucleic Acids for Therapeutic Approach: Tutorial Review.
    Geinguenaud F; Guenin E; Lalatonne Y; Motte L
    ACS Chem Biol; 2016 May; 11(5):1180-91. PubMed ID: 26950048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re-Engineering RNA Molecules into Therapeutic Agents.
    Egli M; Manoharan M
    Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyaluronan-based delivery of therapeutic oligonucleotides for treatment of human diseases.
    Ossipov DA
    Expert Opin Drug Deliv; 2019 Jun; 16(6):621-637. PubMed ID: 31072142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reality check: lipid-oligonucleotide conjugates for therapeutic applications.
    Goodnow RA
    Expert Opin Drug Discov; 2023 Feb; 18(2):129-134. PubMed ID: 36546308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polyamine-oligonucleotide conjugates: a promising direction for nucleic acid tools and therapeutics.
    Menzi M; Lightfoot HL; Hall J
    Future Med Chem; 2015; 7(13):1733-49. PubMed ID: 26424049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mechanisms of action and patentability of therapeutic oligonucleotides].
    Crouvezier N; Marie AC; Moumné L
    Med Sci (Paris); 2023 Feb; 39(2):111-118. PubMed ID: 36799745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Oligonucleotide therapeutics - an emerging novel class of compounds].
    Wacheck V
    Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptide vectors for the nonviral delivery of nucleic acids.
    Hoyer J; Neundorf I
    Acc Chem Res; 2012 Jul; 45(7):1048-56. PubMed ID: 22455499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intracellular delivery of oligonucleotide conjugates and dendrimer complexes.
    Juliano RL
    Ann N Y Acad Sci; 2006 Oct; 1082():18-26. PubMed ID: 17145920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent preclinical and clinical advances in oligonucleotide conjugates.
    Craig K; Abrams M; Amiji M
    Expert Opin Drug Deliv; 2018 Jun; 15(6):629-640. PubMed ID: 29727206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.